These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 27832967)

  • 41. Blockage of Stat3 enhances the sensitivity of NSCLC cells to PI3K/mTOR inhibition.
    Jin HO; Lee YH; Park JA; Kim JH; Hong SE; Kim HA; Kim EK; Noh WC; Kim BH; Ye SK; Chang YH; Hong SI; Hong YJ; Park IC; Lee JK
    Biochem Biophys Res Commun; 2014 Feb; 444(4):502-8. PubMed ID: 24472538
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma.
    Kirstein MM; Boukouris AE; Pothiraju D; Buitrago-Molina LE; Marhenke S; Schütt J; Orlik J; Kühnel F; Hegermann J; Manns MP; Vogel A
    Liver Int; 2013 May; 33(5):780-93. PubMed ID: 23489999
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
    Martelli AM; Tazzari PL; Tabellini G; Bortul R; Billi AM; Manzoli L; Ruggeri A; Conte R; Cocco L
    Leukemia; 2003 Sep; 17(9):1794-805. PubMed ID: 12970779
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.
    Takeuchi H; Kondo Y; Fujiwara K; Kanzawa T; Aoki H; Mills GB; Kondo S
    Cancer Res; 2005 Apr; 65(8):3336-46. PubMed ID: 15833867
    [TBL] [Abstract][Full Text] [Related]  

  • 45. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.
    Lim HJ; Crowe P; Yang JL
    J Cancer Res Clin Oncol; 2015 Apr; 141(4):671-89. PubMed ID: 25146530
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inactivation of PTEN increases ABCG2 expression and the side population through the PI3K/Akt pathway in adult acute leukemia.
    Huang FF; Wu DS; Zhang L; Yu YH; Yuan XY; Li WJ; Chen XP; Zhao XL; Chen FP; Zeng H
    Cancer Lett; 2013 Aug; 336(1):96-105. PubMed ID: 23603434
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics.
    Liu Q; Kirubakaran S; Hur W; Niepel M; Westover K; Thoreen CC; Wang J; Ni J; Patricelli MP; Vogel K; Riddle S; Waller DL; Traynor R; Sanda T; Zhao Z; Kang SA; Zhao J; Look AT; Sorger PK; Sabatini DM; Gray NS
    J Biol Chem; 2012 Mar; 287(13):9742-9752. PubMed ID: 22223645
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors.
    Bendell JC; Kurkjian C; Infante JR; Bauer TM; Burris HA; Greco FA; Shih KC; Thompson DS; Lane CM; Finney LH; Jones SF
    Invest New Drugs; 2015 Apr; 33(2):463-71. PubMed ID: 25707361
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Phosphatidylinositol 3-Kinase p110α/PTEN Signaling Pathway Is Crucial for HIV-1 Entry.
    Hamada K; Maeda Y; Mizutani A; Okada S
    Biol Pharm Bull; 2019; 42(1):130-138. PubMed ID: 30606984
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells.
    Wagner R; Stübiger G; Veigel D; Wuczkowski M; Lanzerstorfer P; Weghuber J; Karteris E; Nowikovsky K; Wilfinger-Lutz N; Singer CF; Colomer R; Benhamú B; López-Rodríguez ML; Valent P; Grunt TW
    Oncotarget; 2017 Feb; 8(7):11600-11613. PubMed ID: 28086243
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms.
    Kong D; Yamori T
    Cancer Sci; 2007 Oct; 98(10):1638-42. PubMed ID: 17711503
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dormant Intestinal Stem Cells Are Regulated by PTEN and Nutritional Status.
    Richmond CA; Shah MS; Deary LT; Trotier DC; Thomas H; Ambruzs DM; Jiang L; Whiles BB; Rickner HD; Montgomery RK; Tovaglieri A; Carlone DL; Breault DT
    Cell Rep; 2015 Dec; 13(11):2403-2411. PubMed ID: 26686631
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PTEN Inhibition in Human Disease Therapy.
    Pulido R
    Molecules; 2018 Jan; 23(2):. PubMed ID: 29385737
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Current development status and prospect of dual PI3K/mTOR inhibitors for cancer therapy].
    Shiose Y
    Nihon Yakurigaku Zasshi; 2013 Oct; 142(4):156-61. PubMed ID: 24107518
    [No Abstract]   [Full Text] [Related]  

  • 56. Effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor, on DNA-dependent protein kinase.
    Kong D; Yaguchi S; Yamori T
    Biol Pharm Bull; 2009 Feb; 32(2):297-300. PubMed ID: 19182393
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phosphoinositide signalling in cancer: beyond PI3K and PTEN.
    Bunney TD; Katan M
    Nat Rev Cancer; 2010 May; 10(5):342-52. PubMed ID: 20414202
    [TBL] [Abstract][Full Text] [Related]  

  • 58. mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer.
    Zabala-Letona A; Arruabarrena-Aristorena A; Martín-Martín N; Fernandez-Ruiz S; Sutherland JD; Clasquin M; Tomas-Cortazar J; Jimenez J; Torres I; Quang P; Ximenez-Embun P; Bago R; Ugalde-Olano A; Loizaga-Iriarte A; Lacasa-Viscasillas I; Unda M; Torrano V; Cabrera D; van Liempd SM; Cendon Y; Castro E; Murray S; Revandkar A; Alimonti A; Zhang Y; Barnett A; Lein G; Pirman D; Cortazar AR; Arreal L; Prudkin L; Astobiza I; Valcarcel-Jimenez L; Zuñiga-García P; Fernandez-Dominguez I; Piva M; Caro-Maldonado A; Sánchez-Mosquera P; Castillo-Martín M; Serra V; Beraza N; Gentilella A; Thomas G; Azkargorta M; Elortza F; Farràs R; Olmos D; Efeyan A; Anguita J; Muñoz J; Falcón-Pérez JM; Barrio R; Macarulla T; Mato JM; Martinez-Chantar ML; Cordon-Cardo C; Aransay AM; Marks K; Baselga J; Tabernero J; Nuciforo P; Manning BD; Marjon K; Carracedo A
    Nature; 2017 Jul; 547(7661):109-113. PubMed ID: 28658205
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of phosphoinositide 3-kinase on protease-induced acute and chronic lung inflammation, remodeling, and emphysema in rats.
    Fang X; Li K; Tao X; Chen C; Wang X; Wang L; Wang DC; Zhang Y; Bai C; Wang X
    Chest; 2013 Apr; 143(4):1025-1035. PubMed ID: 23188423
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rapamycin treatment suppresses epileptogenic activity in conditional Pten knockout mice.
    D'Arcangelo G
    Cell Cycle; 2010 Jul; 9(13):2487-8. PubMed ID: 21504089
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.